AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune announced a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support the development of ACI-7104 in early Parkinson’s disease. The funds will extend Part 1 of the ongoing Phase 2 VacSYn trial by two years to assess long-term safety and efficacy, with final data expected in the second half of 2026.
Key figures
- Drug Name
- ACI-7104
- Phase Of Trial
- Phase 2
- Grant amount usd
- 4000000
- Final data expected
- H2 2026
- Trial extension duration
- 2 years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.